Background Quality of life of patients with rheumatoid arthritis (RA) and biological therapy can be influenced by several factors, not only the response to treatment. Amyloidosis can be one of this
Objectives We investigated if the quality of life of patients with rheumatoid arthritis and various biological therapies is influenced by the existence of amyloidosis
Methods We evaluated 113 RA patients (21 men and 92 women) with anti-TNF treatment between June and December 2011. We measured the patients’ health-related quality of life using the health assessment questionnaire (HAQ) and visual analog scales for global estimate of status (VAS - GS). All patients were clinically and biologically evaluated. In some patients with HAQ>1 we performed biopsy of abdominal fat to appreciate the existence of amyloidosis using special stain.
Results The mean age was 53.2 years (range 21–73) and the mean disease duration was 172.9 months (range 18–476). The mean duration of biological treatment was 47.4 months (range 6-132). 32 patients have HAQ>1 and the fat biopsy were performed at 16 of them. We found statistically significant differences between the 2 groups (with or without amyloidosis) and they were recorded between CRP value, VASpatient (p<0.02) and ESR value (p<0.04). We didn’t find any significant difference between treatment duration, number of DMARDs, different anti-TNFα agents, swollen joints, DAS 28, sex, other comorbidities.
Conclusions Amyloidosis is an entity that can influence the quality of life of patients with rheumatoid arthritis. We didn’t found any significant correlation with type of biological treatment. Further studies will be necessary to complete this results
Disclosure of Interest None Declared